Similar articles

• Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

  Malizzia LJ, Hsu A. Malizzia LJ, et al. Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Clin J Oncol Nurs. 2008. PMID: 18676330 Review.
• Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

  Figlin RA. Figlin RA. Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Nat Clin Pract Oncol. 2008. PMID: 18607393 Review.
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Hudes G, et al. N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838. N Engl J Med. 2007. PMID: 17538086 Clinical Trial.
• Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.

  Jafri M, Douis H, Porfiri E. Jafri M, et al. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):657-8. doi: 10.1016/j.clon.2008.06.002. Epub 2008 Jul 21. Clin Oncol (R Coll Radiol). 2008. PMID: 18644704 No abstract available.
• Temsirolimus for advanced renal cell carcinoma.

  Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2007 Nov;5(11):893. Clin Adv Hematol Oncol. 2007. PMID: 18185488 No abstract available.